Recent studies have shown that combining venetoclax with small-molecule inhibitors (such as FLT3 inhibitors, MCL-1 inhibitors, and cyclin-dependent kinase 9 inhibitors) has a synergistic effect in the treatment of high-risk AML [34–37]. Here, CDK9 is linked to acute myeloid leukemia.